Is immune-mediated heparin-induced thrombocytopenia less common with low-molecular-weight heparins, and should a low-molecular-weight heparin be used in a patient who develops this complication with standard, unfractionated heparin? - Molecular mechanisms and therapeutic utility

Author: Howe A.M.   Allerman A.A.  

Publisher: Elsevier

ISSN: 1088-3371

Source: Disease Management and Clinical Outcomes, Vol.1, Iss.6, 1998-11, pp. : 207-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content